Related Experiment Video
Updated: Jan 9, 2026
09:51
Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
Published on: July 26, 2017
12.9K
Discovery of selective TLR9 antagonists via machine learning-driven structural modeling and experimental validation.
Abdul Waheed Khan1, Naila Qayyum2, Abdul Manan1
1Department of Molecular Science and Technology, Ajou University, Suwon, 16499, Republic of Korea.
International Journal of Biological Macromolecules
|December 10, 2025
Summary
Researchers discovered novel small-molecule antagonists, TRin7 and TRin8, targeting Toll-like receptor 9 (TLR9). These compounds effectively inhibit TLR9-mediated inflammation without significant toxicity, offering therapeutic potential for inflammatory diseases and cancer.
Area of Science:
- Immunology and Pharmacology
- Computational Drug Discovery
Background:
- Toll-like receptor 9 (TLR9) senses CpG DNA, crucial for host defense but implicated in chronic inflammation, autoimmunity, and cancer when dysregulated.
- Existing TLR9 antagonists have limitations including off-target effects, poor pharmacokinetics, and safety concerns, necessitating the development of novel inhibitors.
Purpose of the Study:
- To discover and characterize novel, selective small-molecule antagonists of Toll-like receptor 9 (TLR9).
- To address the limitations of current TLR9 inhibitors by developing compounds with improved efficacy and safety profiles.
Main Methods:
- Integrated computational approaches including machine learning-based QSAR, molecular docking, pharmacophore modeling, and molecular dynamics simulations.
- Experimental validation using in vitro assays with murine RAW264.7 macrophages and human Daudi cells to assess cytokine production and TLR pathway selectivity.
- Mechanistic studies to investigate the disruption of TLR9-CpG DNA binding and downstream signaling pathways (NF-κB, MAPK).
Main Results:
- Two novel TLR9 inhibitors, TRin7 and TRin8, were identified and prioritized based on computational predictions and binding free energies.
- TRin7 and TRin8 selectively suppressed CpG ODN2395-induced cytokine production (TNF-α, IL-6, MCP-1, IL-8) without affecting other TLR pathways or causing significant toxicity.
- Mechanistic studies confirmed that TRin7 and TRin8 disrupt TLR9-CpG DNA binding, inhibit NF-κB and MAPK signaling, and reduce COX2/NOS2 expression, with TRin7 showing slightly higher potency.
Conclusions:
- TRin7 and TRin8 represent promising small-molecule antagonists for TLR9, demonstrating selective inhibition and a favorable safety profile.
- The integrated computational-experimental strategy proved effective for rational drug discovery of novel TLR9 inhibitors.
- These findings support the therapeutic potential of targeting TLR9 for conditions associated with its dysregulation.
